B7-1/B7-2/CD28/CTLA-4 is the most extensively characterized of these pathways. Interactions between members of the B7 ligand and CD28 receptor families generate positive costimulation and negative coinhibition, which are of central importance in regulating T cell responses (1-3). The disclosures of these publications, and all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.
Download prism software albert einstein college of medicine full#
Full citations for these references may be found at the end of the specification. Throughout this application various publications are referred to in parentheses. The government has certain rights in the invention.
This invention was made with government support under grant number DK083076 awarded by the National Institutes of Health and PC094137 awarded by the Department of Defense. The method of claim 1, wherein the HHLA2-bearing tumor is a HHLA2-bearing tumor of breast, esophagus, liver, lung, bladder, colon or rectum, ovary, thyroid, pancreas, kidney, prostate, or is a malignant melanoma. The method of claim 1, wherein the anti-HHLA2 antibody or HHLA2-binding fragment is conjugated to a cytotoxic agent, an anti-cancer drug or a chemotherapeutic agent.ħ. The method of claim 1, wherein the antibody is a monoclonal antibody.Ħ. The method of claim 1, wherein the antibody is a humanized antibody, a chimeric antibody or an isolated human antibody.ĥ. The method of claim 1, wherein the HHLA2 protein comprises consecutive amino acid residues having the sequence set forth in SEQ ID NO: 1.Ĥ. The method of claim 1, wherein the HHLA2 to which the anti-HHLA2antibody is directed is a human HHLA2 protein.ģ. A method of treating a HHLA2-bearing tumor in a subject, comprising administering to the subject an amount of an anti-HHLA2antibody, or an HHLA2-binding fragment of an anti-HHLA2antibody, effective to treat the HHLA2-bearing tumor.Ģ.